GALT (Galectin Therapeutics) Long-Term Debt: $135.71 Mil (As of Mar. 2026)


GALT Galectin Therapeutics Inc GALT
22 GF Score
Price $4.61
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics Long-Term Debt?

Galectin Therapeutics GALT 22 Long-Term Debt is $135.71 Mil as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

Galectin Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $135.71 Mil.

Galectin Therapeutics's quarterly Long-Term Debt increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($133.74 Mil) and increased from Dec. 2025 ($133.74 Mil) to Mar. 2026 ($135.71 Mil).

Galectin Therapeutics's annual Long-Term Debt increased from Dec. 2023 ($71.74 Mil) to Dec. 2024 ($85.11 Mil) and increased from Dec. 2024 ($85.11 Mil) to Dec. 2025 ($133.74 Mil).

Galectin Therapeutics  (NAS:GALT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Galectin Therapeutics Long-Term Debt Related Terms

Galectin Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Long-Term Debt Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.05 39.83 71.74 85.11 133.74

Galectin Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.81 120.46 0.00 133.74 135.71
GALT
22GF Score
Galectin Therapeutics Inc GALT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $135.71 Mil mean?
Galectin Therapeutics (GALT) has a Long-Term Debt of $135.71 Mil as of Mar. 2026.
Is Galectin Therapeutics' Long-Term Debt too high?
Galectin Therapeutics' current Long-Term Debt is $135.71 Mil. Overall, Galectin Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' Long-Term Debt compare to PALI and IRD?
Galectin Therapeutics' Long-Term Debt of $135.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Galectin Therapeutics's current Long-Term Debt is $135.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current Long-Term Debt of $135.71 Mil. The current Long-Term Debt is $135.71 Mil. Galectin Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current Long-Term Debt is $135.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
22GF Score

Get the complete analysis for GALT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price